P432: VALIDATION OF LIMIT OF QUANTIFICATION APPROACH BASED FLOW CYTOMETRY FOR MEASURABLE RESIDUAL DISEASE ASSESSMENT IN ACUTE MYELOID LEUKEMIA IN THE HOVON-SAKK-132 TRIAL
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2023-08-01
|
| Series: | HemaSphere |
| Online Access: | http://journals.lww.com/10.1097/01.HS9.0000968636.18625.e3 |
| _version_ | 1827331350217097216 |
|---|---|
| author | Jesse Tettero Raffaele Palmieri Lok Lam Ngai Costa Bachas Valentina Arena Dimitri Breems Thomas Fischer Bjorn Tore Gjertsen Laimonas Griškevičius Gunnar Juliusson Johan Maertens Markus Manz Luca Maurillo Thomas Pabst Jakob Passweg Alfonso Piciocchi Kimmo Porkka Bob Löwenberg Adriano Venditti Gert Ossenkoppele Francesco Buccisano Jacqueline Cloos |
| author_facet | Jesse Tettero Raffaele Palmieri Lok Lam Ngai Costa Bachas Valentina Arena Dimitri Breems Thomas Fischer Bjorn Tore Gjertsen Laimonas Griškevičius Gunnar Juliusson Johan Maertens Markus Manz Luca Maurillo Thomas Pabst Jakob Passweg Alfonso Piciocchi Kimmo Porkka Bob Löwenberg Adriano Venditti Gert Ossenkoppele Francesco Buccisano Jacqueline Cloos |
| author_sort | Jesse Tettero |
| collection | DOAJ |
| first_indexed | 2024-03-07T16:34:54Z |
| format | Article |
| id | doaj.art-dc2e23635db44b06803fbc4728b8a8f8 |
| institution | Directory Open Access Journal |
| issn | 2572-9241 |
| language | English |
| last_indexed | 2024-03-07T16:34:54Z |
| publishDate | 2023-08-01 |
| publisher | Wiley |
| record_format | Article |
| series | HemaSphere |
| spelling | doaj.art-dc2e23635db44b06803fbc4728b8a8f82024-03-03T10:04:25ZengWileyHemaSphere2572-92412023-08-017e18625e310.1097/01.HS9.0000968636.18625.e3202308003-00333P432: VALIDATION OF LIMIT OF QUANTIFICATION APPROACH BASED FLOW CYTOMETRY FOR MEASURABLE RESIDUAL DISEASE ASSESSMENT IN ACUTE MYELOID LEUKEMIA IN THE HOVON-SAKK-132 TRIALJesse Tettero0Raffaele Palmieri1Lok Lam Ngai2Costa Bachas3Valentina Arena4Dimitri Breems5Thomas Fischer6Bjorn Tore Gjertsen7Laimonas Griškevičius8Gunnar Juliusson9Johan Maertens10Markus Manz11Luca Maurillo12Thomas Pabst13Jakob Passweg14Alfonso Piciocchi15Kimmo Porkka16Bob Löwenberg17Adriano Venditti18Gert Ossenkoppele19Francesco Buccisano20Jacqueline Cloos211 Amsterdam UMC, location Vrije Universiteit, Department of Hematology, Amsterdam, The Netherlands2 University of Rome “Tor Vergata”, Department of Biomedicine and Prevention, Rome, Italy1 Amsterdam UMC, location Vrije Universiteit, Department of Hematology, Amsterdam, The Netherlands1 Amsterdam UMC, location Vrije Universiteit, Department of Hematology, Amsterdam, The Netherlands3 GIMEMA Data Center, Rome, Italy4 Ziekenhuis Netwerk Antwerpen, Department of Hematology, Antwerpen, Belgium5 Otto-von-Guericke-University Magdeburg, Department of Hematology and Oncology, Magdeburg, Germany6 Haukeland University Hospital, Department of Medicine, Hematology Section, Bergen, Norway7 Vilnius University Hospital Santaros Klinikos and Vilnius University, Hematology, Oncology, Transfusion Medicine Center, Vilnius, Lithuania8 Skanes University Hospital, Department of Hematology, Lund, Sweden9 University Hospital Gasthuisberg, Department of Hematology, Leuven, Belgium10 University Hospital of Zürich, Department of Medical Oncology and Hematology, Zürich, Switzerland2 University of Rome “Tor Vergata”, Department of Biomedicine and Prevention, Rome, Italy11 Inselspital, University Hospital, Department of Medical Oncology, Bern, Switzerland12 University Hospital, Basel, Department of Hematology, Basel, Switzerland3 GIMEMA Data Center, Rome, Italy13 Helsinki University Hospital Cancer Center, Department of Hematology, Helsinki, Finland14 Erasmus University Medical Center (MC) and Erasmus MC Cancer Institute, Rotterdam, The Netherlands2 University of Rome “Tor Vergata”, Department of Biomedicine and Prevention, Rome, Italy1 Amsterdam UMC, location Vrije Universiteit, Department of Hematology, Amsterdam, The Netherlands2 University of Rome “Tor Vergata”, Department of Biomedicine and Prevention, Rome, Italy1 Amsterdam UMC, location Vrije Universiteit, Department of Hematology, Amsterdam, The Netherlandshttp://journals.lww.com/10.1097/01.HS9.0000968636.18625.e3 |
| spellingShingle | Jesse Tettero Raffaele Palmieri Lok Lam Ngai Costa Bachas Valentina Arena Dimitri Breems Thomas Fischer Bjorn Tore Gjertsen Laimonas Griškevičius Gunnar Juliusson Johan Maertens Markus Manz Luca Maurillo Thomas Pabst Jakob Passweg Alfonso Piciocchi Kimmo Porkka Bob Löwenberg Adriano Venditti Gert Ossenkoppele Francesco Buccisano Jacqueline Cloos P432: VALIDATION OF LIMIT OF QUANTIFICATION APPROACH BASED FLOW CYTOMETRY FOR MEASURABLE RESIDUAL DISEASE ASSESSMENT IN ACUTE MYELOID LEUKEMIA IN THE HOVON-SAKK-132 TRIAL HemaSphere |
| title | P432: VALIDATION OF LIMIT OF QUANTIFICATION APPROACH BASED FLOW CYTOMETRY FOR MEASURABLE RESIDUAL DISEASE ASSESSMENT IN ACUTE MYELOID LEUKEMIA IN THE HOVON-SAKK-132 TRIAL |
| title_full | P432: VALIDATION OF LIMIT OF QUANTIFICATION APPROACH BASED FLOW CYTOMETRY FOR MEASURABLE RESIDUAL DISEASE ASSESSMENT IN ACUTE MYELOID LEUKEMIA IN THE HOVON-SAKK-132 TRIAL |
| title_fullStr | P432: VALIDATION OF LIMIT OF QUANTIFICATION APPROACH BASED FLOW CYTOMETRY FOR MEASURABLE RESIDUAL DISEASE ASSESSMENT IN ACUTE MYELOID LEUKEMIA IN THE HOVON-SAKK-132 TRIAL |
| title_full_unstemmed | P432: VALIDATION OF LIMIT OF QUANTIFICATION APPROACH BASED FLOW CYTOMETRY FOR MEASURABLE RESIDUAL DISEASE ASSESSMENT IN ACUTE MYELOID LEUKEMIA IN THE HOVON-SAKK-132 TRIAL |
| title_short | P432: VALIDATION OF LIMIT OF QUANTIFICATION APPROACH BASED FLOW CYTOMETRY FOR MEASURABLE RESIDUAL DISEASE ASSESSMENT IN ACUTE MYELOID LEUKEMIA IN THE HOVON-SAKK-132 TRIAL |
| title_sort | p432 validation of limit of quantification approach based flow cytometry for measurable residual disease assessment in acute myeloid leukemia in the hovon sakk 132 trial |
| url | http://journals.lww.com/10.1097/01.HS9.0000968636.18625.e3 |
| work_keys_str_mv | AT jessetettero p432validationoflimitofquantificationapproachbasedflowcytometryformeasurableresidualdiseaseassessmentinacutemyeloidleukemiainthehovonsakk132trial AT raffaelepalmieri p432validationoflimitofquantificationapproachbasedflowcytometryformeasurableresidualdiseaseassessmentinacutemyeloidleukemiainthehovonsakk132trial AT loklamngai p432validationoflimitofquantificationapproachbasedflowcytometryformeasurableresidualdiseaseassessmentinacutemyeloidleukemiainthehovonsakk132trial AT costabachas p432validationoflimitofquantificationapproachbasedflowcytometryformeasurableresidualdiseaseassessmentinacutemyeloidleukemiainthehovonsakk132trial AT valentinaarena p432validationoflimitofquantificationapproachbasedflowcytometryformeasurableresidualdiseaseassessmentinacutemyeloidleukemiainthehovonsakk132trial AT dimitribreems p432validationoflimitofquantificationapproachbasedflowcytometryformeasurableresidualdiseaseassessmentinacutemyeloidleukemiainthehovonsakk132trial AT thomasfischer p432validationoflimitofquantificationapproachbasedflowcytometryformeasurableresidualdiseaseassessmentinacutemyeloidleukemiainthehovonsakk132trial AT bjorntoregjertsen p432validationoflimitofquantificationapproachbasedflowcytometryformeasurableresidualdiseaseassessmentinacutemyeloidleukemiainthehovonsakk132trial AT laimonasgriskevicius p432validationoflimitofquantificationapproachbasedflowcytometryformeasurableresidualdiseaseassessmentinacutemyeloidleukemiainthehovonsakk132trial AT gunnarjuliusson p432validationoflimitofquantificationapproachbasedflowcytometryformeasurableresidualdiseaseassessmentinacutemyeloidleukemiainthehovonsakk132trial AT johanmaertens p432validationoflimitofquantificationapproachbasedflowcytometryformeasurableresidualdiseaseassessmentinacutemyeloidleukemiainthehovonsakk132trial AT markusmanz p432validationoflimitofquantificationapproachbasedflowcytometryformeasurableresidualdiseaseassessmentinacutemyeloidleukemiainthehovonsakk132trial AT lucamaurillo p432validationoflimitofquantificationapproachbasedflowcytometryformeasurableresidualdiseaseassessmentinacutemyeloidleukemiainthehovonsakk132trial AT thomaspabst p432validationoflimitofquantificationapproachbasedflowcytometryformeasurableresidualdiseaseassessmentinacutemyeloidleukemiainthehovonsakk132trial AT jakobpassweg p432validationoflimitofquantificationapproachbasedflowcytometryformeasurableresidualdiseaseassessmentinacutemyeloidleukemiainthehovonsakk132trial AT alfonsopiciocchi p432validationoflimitofquantificationapproachbasedflowcytometryformeasurableresidualdiseaseassessmentinacutemyeloidleukemiainthehovonsakk132trial AT kimmoporkka p432validationoflimitofquantificationapproachbasedflowcytometryformeasurableresidualdiseaseassessmentinacutemyeloidleukemiainthehovonsakk132trial AT boblowenberg p432validationoflimitofquantificationapproachbasedflowcytometryformeasurableresidualdiseaseassessmentinacutemyeloidleukemiainthehovonsakk132trial AT adrianovenditti p432validationoflimitofquantificationapproachbasedflowcytometryformeasurableresidualdiseaseassessmentinacutemyeloidleukemiainthehovonsakk132trial AT gertossenkoppele p432validationoflimitofquantificationapproachbasedflowcytometryformeasurableresidualdiseaseassessmentinacutemyeloidleukemiainthehovonsakk132trial AT francescobuccisano p432validationoflimitofquantificationapproachbasedflowcytometryformeasurableresidualdiseaseassessmentinacutemyeloidleukemiainthehovonsakk132trial AT jacquelinecloos p432validationoflimitofquantificationapproachbasedflowcytometryformeasurableresidualdiseaseassessmentinacutemyeloidleukemiainthehovonsakk132trial |